A multi-site trial of an electronic health integrated physical activity promotion intervention in breast and endometrial cancers survivors: MyActivity study protocol

Despite the known benefits of moderate-to-vigorous physical activity (MVPA) for breast and endometrial cancer survivors, most are insufficiently active, interventions response is heterogeneous, and MVPA programming integration into cancer care is limited. A stepped care approach, in which the least resource-intensive intervention is delivered first and additional components are added based on individual response, is one strategy to enhance uptake of physical activity programming. However, the most effective intervention augmentation strategies are unknown. In this singly randomized trial of post-treatment, inactive breast and endometrial cancer survivors (n = 323), participants receive a minimal intervention including a Fitbit linked with their clinic's patient portal and, in turn, the electronic health record (EHR) with weekly feedback delivered via the portal. MVPA progress summaries are sent to participants' oncology team via the EHR. MVPA adherence is evaluated at 4, 8, 12, 16 and 20 weeks; non-responders (those meeting ≤80% of the MVPA goal over previous 4 weeks) at each timepoint are randomized once for the remainder of the 24-week intervention to one of two "step-up" conditions: (1) online gym or (2) coaching calls, while responders continue with the minimal Fitbit+EHR intervention. The primary outcome is ActiGraph-measured MVPA at 24 and 48 weeks. Secondary outcomes include symptom burden and functional performance at 24 and 48 weeks. This trial will inform development of an effective, scalable, and tailored intervention for survivors by identifying non-responders and providing them with the intervention augmentations necessary to increase MVPA and improve health outcomes. Clinical Trials Registration # NCT04262180.

Cerebrovascular changes in a rat model of moderate closed-head injury

We have developed and tested a rat (Wistar) model of moderate concussion. Concussion is produced by controlled and repeatable mechanical fixed, closed-head injury. Moderate concussion in this model is characterized by 4 to 10 minutes of unconsciousness, absence of skull fractures or brain contusions, and few, if any, acute neurologic symptoms. By 2 hours postinjury, the subsequent trauma is further characterized by regional and global increases in cerebrovascular permeability and decreases in cerebral blood flow. Such changes are accompanied by brain swelling and two phases of elevated intracranial pressure; one lasting about 5 hours with a peak of about 10 mmHg, the other lasting more than 3 days postinjury with a peak of about 30 mmHg. Regional neurohistologic damage detected between 3 and 4 days postinjury correlates for the most part with earlier changes in regional permeability and blood flow. Significant morphologic changes which are characterized by patchy neuronal degeneration can be found in numerous forebrain locations, particularly in the frontal (coup) and entorhinal (contre coup) cortices. These observations have important parallels in human head trauma and suggest that this reliable physiological model may be a useful, relatively simple and inexpensive tool for investigating the mechanisms and therapeutics of head trauma.

The relevance of a First-World therapeutic drug monitoring service to the treatment of epilepsy in Third-World conditions

In May 1988 a Therapeutic Drug Monitoring (TDM) service for anti-epileptic drugs was established at Prince Mshiyeni Memorial Hospital. This service was offered as a multidisciplinary team approach involving sisters, doctors, social workers and pharmacists at an epilepsy clinic. Statistics gathered over a 13-month period showed that: (i) epileptic patient numbers increased from 52 to 211 per 4-week cycle, while patients requiring TDM decreased from 40 to 20 per cycle; (ii) phenytoin was the most frequently prescribed anticonvulsant, followed by carbamazepine and phenobarbitone, throughout the period; (iii) TDM did not alter prescribing patterns--approximately 90% of patients were on monotherapy at the beginning and at the end of the assessment period; (iv) 471 serum levels were measured in 280 patients over 13 months. Phenytoin serum levels constituted the majority (53%) followed by carbamazepine (33%), phenobarbitone (12%) and valproate (2%); (v) of the levels measured in 24 patients taking phenytoin 300 mg/d who were experiencing neither seizures nor side-effects, 38% of levels were in the potentially toxic range; and (vi) well-controlled patients increased from 36% in the first cycle to 60% in the last cycle. A TDM service is very useful in a Third-World setting and can assist in conserving scarce sources provided it is utilised within a holistic treatment framework.